Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-03-20
2007-03-20
Canella, Karen A. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S007800, C435S007920, C435S040500, C436S064000, C436S501000, C436S813000
Reexamination Certificate
active
09640952
ABSTRACT:
Method and kits are provided for the detection and diagnosis of metastatic disease. More particularly, the methods and kits employ compounds that can detect EphA2, a specific epithelial cell tyrosine kinase that is overexpressed in metastatic tumor cells. In one embodiment the compound is an antibody capable of binding to an epitope of EphA2.
REFERENCES:
patent: 4472371 (1984-09-01), Burchiel et al.
patent: 4704692 (1987-11-01), Ladner
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5001225 (1991-03-01), Taylor
patent: 5457048 (1995-10-01), Pasquale et al.
patent: 5514554 (1996-05-01), Bacus
patent: 5585089 (1996-12-01), Queen et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5811098 (1998-09-01), Plowman et al.
patent: 5824303 (1998-10-01), Bartley et al.
patent: 5872223 (1999-02-01), Uckun
patent: 5876949 (1999-03-01), Dreyfuss et al.
patent: 5981245 (1999-11-01), Fox et al.
patent: 6057105 (2000-05-01), Hoon et al.
patent: 6174670 (2001-01-01), Wittwer et al.
patent: 2001/0031252 (2001-10-01), Low et al.
patent: 2001/0031262 (2001-10-01), Low et al.
patent: 2004/0028685 (2004-02-01), Kinch et al.
patent: 2004/0091486 (2004-05-01), Kinch et al.
patent: WO 93/00425 (1993-01-01), None
patent: WO 94/04679 (1994-03-01), None
patent: WO 94/29348 (1994-12-01), None
patent: WO 95/15375 (1995-06-01), None
patent: WO 97/15587 (1997-05-01), None
patent: WO 98/43960 (1998-10-01), None
patent: WO 00/30673 (2000-06-01), None
patent: WO 00/37500 (2000-06-01), None
patent: WO 01/12172 (2001-02-01), None
patent: WO 01/12840 (2001-02-01), None
patent: WO 01/12840 (2001-02-01), None
patent: WO 01/47892 (2001-07-01), None
patent: WO 03/099313 (2003-12-01), None
patent: WO 2004/014292 (2004-02-01), None
patent: WO 94/11020 (2004-05-01), None
patent: WO 03/094859 (2004-11-01), None
patent: PCT/US2004/039112 (2004-12-01), None
Zanteck, et al., 1998, Mol. Bio. Cell, 9 (Supp):134a, abstract 773, 38th Annual Meeting of the American Society for Cell Biology.
Kinch, 1998, Hybridoma, vol. 17, No. 3, pp. 227-235.
Khan et al (American Journal of Clinical Pathology, 1984, vol. 81, pp. 184-191).
Lindberg et al (Molecular and Cellular biology, 1990, vol. 10, pp. 6316-6324).
Easty et al (International Journal of Cancer, 1995, vol. 60, pp. 129-136).
The abstract of Chen et al (Journal of Biological Chemistry, 1998, vol. 273, pp. 24670-24675).
Larrick et al (In: Human Hybridomas and Monoclonal Antibodies, Engleman and Foung, Ed.s, 1985, pp. 8-9).
The abstract of Muhlbauer et al (Clinical Cancer Research, May 1999, vol. 5, pp. 1099-1105).
Easty et al (International Journal of Cancer, 1997, vol. 71, pp. 1061-1065).
Kerr and Thorpe (LabFax Immunochemistry, 1994, pp. 115, 157, 191-197).
Campbell (Monoclonal Antibody Technology, 1985, pp. 1-32).
abstract of Terstappen et al (Vox Sanguinis, 1998, 74 suppl. 2, pp. 269-274).
Zelinski et al., “EphA2 Overexpression Causes Tumorigenesis of Mammary Epithelial Cells”,Cancer Research 61:2301-2306 (Mar. 2001).
Biervert et al. “Semiquantitative expression analysis of ephrine-receptor tyrosine kinase mRNA's in a rat model of traumatic brain injury.”Neurosci Lett.2001;315(1-2):25-8.
Blanco et al. “Expression of EphA receptors and ligands during chick cerebellar development.”Mech. Dev.2002;114(1-2):225-9.
Bodansky et al., Ed.,Principles of Peptide Synthesis, Springer-Verlag Inc., NY, 1993, Cover p., Publication p., and Table of Contents.
Bovenkamp et al. “Degenerate PCR-based cloninig method for Eph receptors and analysis of their expression in the developing murine central nervous system and vasculature”DNA Cell Biol.2001;20(4):203-13.
Brantley et al. “Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo.”Oncogene. 2002;21(46):7011-26.
Brodeur et al. Mouse-Human Myeloma Partners for the Production of Heterohybridomas,Monoclonal Antibody Production Techniques and Application1987:51-63.
Bruggemann et al., “Designer mice: the production of human antibody repertoires in transgenic animals”Year Immunol. 1993;7:33-40.
Carter et al. “EphrinA1 -induced cytoskeletal re-organization requires FAK and p130(cas).”Nat Cell Biol. 2002;4(8):565-73.
Cheng et al. “Blockade of EphaA Receptor Tyrosine Kinase Activation Inhibits Vascular Endothelial Cell Growth Factor-Induced Angiogenesis.”Mol Cancer Res. 2002;1(1);2-11.
Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, 1985, p. 77.
Dohn et al. “Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis.”Oncogene. 2001;20(45):6503-15.
Grant,Synthetic Peptides: A User Guide, W.H. Freeman and Co., N.Y., 1992, Cover p., Publication p., and Table of Contents only.
Gussow et al. “Humanization of monoclonal antibodies”Methods Enzymol. 1991;203:99-121.
Harlow et al.,Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York, 1988.
Hartwell et al. “Integrating Genetic Appraoches into the Discovery of Anticancer Drugs”Science1997;278:1064-1068.
Hess et al., “Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: Role of epithelial cell kinase (ECK/EphA2),”Cancer Res., 2001;61:3250-3255.
Kabat et al., “Sequences of Proteins of Immunological Interest,”National Institutes of Health, Bethesda, Md. 1987.
Karam et al. “EphA4 is not required for Purkinje cell compartmentation. Brain Res Dev Brain Res.” 2002;135(1-2):29-38.
Kinch et al. “Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer”Clinical&Experimental Metastasis2003;20:59-68.
Kinch et al “Predictive Value of the EphA2 Receptor Tyrosine Kinase in Lung Cancer Recurrence and Survival”Clin Cancer Res.2003;9(2):613-8.
Koolpe et al. “An ephrin mimetic peptide that selectively targets the EphA2 receptor.”J Biol Chem. 2002;277(49):46974-9.
Kratchmarova et al. “Characterization of promoter region and genomic structure of the murine and human genes encoding Src like adapter protein.”Gene. 2001;262(1-2):267-73.
Lai et al. “Expression of Eph receptors in skeletal muscle and their localization at the neuromuscular junction.”Mol Cell Neurosci. 2001;17(6):1034-47.
Miao et al., “Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation,”Nat. Cell Biol., 2000;2(2):62-69.
Miyazaki et al. “EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma.”Int J Cancer. 2003;103(5):657-63.
Nakamoto et al. “Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis.”Microsc Res Tech. 2002;59(1):58-67.
Naruse-Nakajima et al. “Involvement of EphA2 in the formation of the tail notochord via interaction with ephrinA1.” Mech Dev. 2001;102(1-2):95-105.
NCBI Locus Link Search for “B61” performed Nov. 24, 2003. Http://www.mcbi.nlm.nih.gov/LocusLink/list.cgi.
New England Biolabs Product Catalog, 1996, p. 164.
Nemoto et al., “Overexpression of Protein Tyrosine Kinases in Human Esphageal Cancer,”Pathobiology, 1997;65:195-203.
Nishida et al. “Domain-specific olivocerebellar projection regulated by the EphA-ephrin-A interaction”Development. 2002;129(24):5647-58.
Nowakowski et al. “Structures of the Cancer-Related Aurora-A, FAK, and EphA2 Protein Kinases from Nanovolume Crystallography.”Structure2002;10(12):1659-67.
Ogawa et al. “The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization.”Oncogene. 2000;19(52):6043-52.
Potla et al. “Reduced expression of EphrinA1 (EFNA1) inhibits three-dimensional growth of HT29 colon carcinoma cells.”Cancer Lett.2002;175(2):187-95.
Pratt et al. “Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade”Oncogene. 2002;21(50):7690-9.
R&D Systems, “Recombinant Mouse E
Kinch Michael S.
Zantek Nicole D.
Canella Karen A.
Mueting Raasch & Gebhardt, P.A.
Purdue Research Foundation
LandOfFree
EphA2 as a diagnostic target for metastatic cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with EphA2 as a diagnostic target for metastatic cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EphA2 as a diagnostic target for metastatic cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3786848